SciBrunch

AboutSciBrunch

We are a clinical-stage biotech driven by iterative innovation in small molecule therapeutics. Our pipeline targets clinically validated oncology pathways, with a strategic focus on hard-to-treat malignancies such as PDAC and CRC

By synergizing deep expertise in medicinal chemistry with agile business development, we build differentiated asset portfolios dedicated to delivering novel life-saving treatments to patients worldwide

About

SciBrunch

We are a clinical-stage biotech driven by iterative innovation in small molecule therapeutics. Our pipeline targets clinically validated oncology pathways, with a strategic focus on hard-to-treat malignancies such as PDAC and CRC

By synergizing deep expertise in medicinal chemistry with agile business development, we build differentiated asset portfolios dedicated to delivering novel life-saving treatments to patients worldwide

Focus

M
Annual Incidence of RAS-Mutant PDAC and CRC Patients
Funding
$
M
From Angel and Pre-A Rounds
Pipelines
≥
1 in Phase I, 1 in IND Enabling, 2 in Discovery

Highly Brain-Penetrant Selective PARP1 Inhibitor

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

RAS Pathway Molecular Glue

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

Solid Tumor Indications, Target Withheld

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

Solid Tumor Indications, Target Withheld

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

Highly Brain-Penetrant Selective PARP1 Inhibitor

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

RAS Pathway Molecular Glue

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

Brain-penetrant HER2 (EGFR sparing) selective inhibitor

KRAS G12V (on) molecular glue

R&D

Pipeline

Highly Brain-Penetrant Selective PARP1 Inhibitor

RAS Pathway Molecular Glue

Brain-penetrant HER2 (EGFR sparing) selective inhibitor

KRAS G12V (on) molecular glue


Highly Brain-Penetrant Selective PARP1 Inhibitor
Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer
RAS Pathway Molecular Glue
Pancreatic Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer
Brain-penetrant HER2 (EGFR sparing) selective inhibitor
KRAS G12V (on) molecular glue

Our

Founders



Founder 1

Founder 1

Tao HU, PhD

FounderChairmanCEO

DDr. Hu brings more than 20 years of experience in drug discovery,operational management, and business development. He previously held senior executive roles at WuXi AppTec, where he oversaw a wide variety of



Founder 1

Founder 1

Yang ZHANG, PhD

Co-FounderCSO

Dr. Zhang is a seasoned medicinal chemist with over 20 years of experience in drug discovery. Prior to founding SciBrunch Therapeutics, he served as Vice President at WuXi AppTec's DDSU, where he successfully delivered more than 30 preclinical projects with competitive advantages to both domestic and international clients.

Tao HU

FounderChairmanCEO



Yang ZHANG

Co-FounderCSO



Our

Investors



Hankang Capital

BioTrack Capital

HighLight Capital

LongRiver Investments

Elikon Venture

InnoPinnacle Fund

News Center

Stay up to date with our latest official announcements and corporate developments, all in one dedicated hub

News 1

SciBrunch Therapeutics Completes Over 35 Million Pre-A Round Financing, Totaling 65 Million in Two Recent Rounds2026-04-21

News 1

First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR10202026-04-21

News 1

SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs2026-04-21